Uni-Bio Science Group Honored with SCMP "Company of the Year" Award

[ Hong Kong, December  16th,  2025] Uni-Bio  Science  Group Limited ("Uni-Bio" or  "the Group") has recently been honored with two prestigious industry awards, recognizing its outstanding  performance  in  biopharmaceuticals  and  steadfast  commitment  to  sustainable development. The Group first received the "2025 Most Promising ESG Potential Award for Hong  Kong  Stocks"  at  the  inaugural  China  "ESG  &  Enterprise  Value  Growth"  Summit. Subsequently, it was invited to attend the "Business Awards 2025" ceremony organized by the South China Morning Post (SCMP), where it stood out among numerous market leaders to be honored with the "Company of the Year" award.

Notably, this year’s SCMP "Business Awards 2025" winners list featured a constellation of stars. The Group was honored alongside internationally renowned companies, such as McDonald's Hong Kong and Gleneagles Hong Kong, for the "Company of the Year" award. This recognition highlights the Group’s high acclaim from international mainstream media and professional institutions   across   multiple   dimensions,   including   financial   robustness,   technological innovation, and depth of ESG practices.

Authoritative Evaluation System Ensures Award Credibility

Founded in 1903, SCMP is one of Hong Kong's oldest and most internationally influential English-language media outlets. Its awards are renowned within the industry for an independent and impartial evaluation system, aiming to honor enterprises and leaders who have made significant contributions to business innovation and economic development in Hong Kong, the Greater Bay Area, and across Asia. The evaluation criteria cover core areas such as financial

growth,  innovation  breakthroughs,  ESG  practices,   strategic   adaptability,   and   industry reputation.

The selection process is rigorous and standardized: This year's awards received 43 nominations from  industry  peers,   spanning  six  categories  including   "Business  Owner  of  the  Year," "Corporate Executive of the Year," and "Company of the Year." All nomination materials were processed  by  the  awards'  knowledge  partner—the  Chartered  Institute  of  Management Accountants (CIMA)—to standardize them into comparable metrics. Subsequently, a judging panel of 11 senior industry experts determined the final winners through confidential voting. The involvement of CIMA, the world's largest professional body of management accountants, further ensures the professionalism and credibility of the selection results.

Strategic Alignment and Honors as Motivation

At the awards ceremony, SCMP CEO Catherine stated, "We are committed to establishing this award  as  a  core  platform   for  cross-sectoral  innovation,  transformative   leadership,  and sustainable growth in Asia, while also serving as a strategic bridge connecting Hong Kong's business community with the accelerating integration of the Greater Bay Area."

This vision aligns closely with Uni-Bio’s development strategy of establishing its foothold in the  Greater  Bay Area  while  expanding  its  global  reach.  In  recent  years,  the  Group  has consistently increased investment in cutting-edge fields such as synthetic biology, complex polypeptides, and regenerative medicine. It is building an innovative pipeline covering four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT (ear, nose, and throat) regeneration. Concurrently, the Group is advancing its ESG governance framework,   integrating   environmental   responsibility,   employee   well-being,   and   social contribution throughout its entire operational cycle.

Moving forward, Uni-Bio will continue to uphold its corporate mission, transforming honors into  momentum  for  development.  It  remains  dedicated  to  pioneering  the  research  and translation of cutting-edge biotechnologies to higher standards, while deeply embedding ESG principles into every aspect of R&D, production, commercialization, and corporate governance. The  Group  aims  to  inject  new  momentum  into  the  high-quality  development  of  the biopharmaceutical industry and contribute more wisdom and strength to global health and well- being.

About Uni-Bio Science：

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next- generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal  regeneration,  skin  regeneration,  ocular  regeneration,  and  ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics,  high-value  generic  drugs,  and  medical  aesthetics.  The  Group  operates  GMP- compliant  production  bases  in  Beijing,  Dongguan,  and  Shenzhen,  with  fully  integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.